Clinical meaning
Prenatal screening employs probabilistic methodology to identify pregnancies at increased risk for chromosomal aneuploidy, structural anomalies, and genetic conditions, enabling informed reproductive decision-making. The fundamental distinction between screening (risk stratification using non-invasive methods) and diagnostic testing (definitive diagnosis requiring invasive procedures with procedural risk) is critical for accurate patient counseling. Screening performance is characterized by sensitivity (detection rate), specificity, false-positive rate, and positive predictive value (PPV) — importantly, PPV is heavily influenced by disease prevalence (maternal age-related risk), so a positive cfDNA result in a 25-year-old has a lower PPV than the same result in a 40-year-old despite identical test sensitivity. Chromosomal aneuploidies arise from nondisjunction during meiotic cell division, where homologous chromosomes (meiosis I) or sister chromatids (meiosis II) fail to separate, producing gametes with extra or missing chromosomes. Maternal age is the strongest risk factor because oocytes remain arrested in meiosis I from fetal development until ovulation — decades of arrest allows degradation of cohesin proteins that hold chromosomes together, increasing nondisjunction risk (trisomy 21 risk: 1:1250 at age 25, 1:350 at age 35, 1:100 at age 40, 1:30 at age 45). Biochemical markers used in screening reflect fetoplacental physiology: PAPP-A (pregnancy-associated plasma protein A) is a metalloproteinase produced by trophoblast that cleaves IGF binding proteins to increase IGF bioavailability for placental growth — low PAPP-A in trisomy 21 reflects impaired trophoblast function. Free beta-hCG is elevated in trisomy 21 because the abnormal placenta produces excess hCG. Maternal serum alpha-fetoprotein (MSAFP) is synthesized by the fetal liver and normally present in low levels in maternal serum — elevated MSAFP indicates disruption of fetal integument (open neural tube defects allow AFP to leak into amniotic fluid and then into maternal circulation) or increased fetoplacental transfer (multiple gestation, placental abnormalities). Inhibin A (elevated in trisomy 21) and unconjugated estriol (low in trisomy 21, reflecting impaired fetoplacental steroid synthesis) complete the quad screen panel. Carrier screening identifies asymptomatic heterozygous carriers of autosomal recessive conditions: both parents must carry the same mutation for a 25% per-pregnancy risk to the offspring. ACOG recommends universal carrier screening for cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies, with expanded panels (100+ conditions) available by patient choice.